Ankylosing spondylitis (AS) involves chronic inflammation; why does TNF-alpha blockade eventually lose efficacy in some AS patients?

💡 Explanation

TNF-alpha blockade initially reduces inflammation. However, other cytokines and inflammatory mediators can compensate over time, leading to inflammation via alternative pathways; therefore, TNF-alpha blockade loses efficacy rather than antibody degradation or receptor downregulation fully explaining the effect.

• Why does hyperpigmentation become more pronounced following an inflammatory skin condition like eczema?
• Why does escalating drug use often lead to compulsive behavior despite diminishing euphoric effects in the reward circuitry?
• If a researcher introduces a calcium channel blocker into a muscle fiber undergoing repeated stimulation, which consequence follows regarding muscle contraction?
• Which outcome causes increased fracture risk when bone adapts to disuse?
• If a mutation reduces the functionality of the retinal pigment epithelium (RPE) in the eye, which consequence involving nutrient transport to photoreceptors is most likely?
• Following thyroid gland removal, why does TSH initially rise despite exogenous thyroxine (T4) administration?